Wells Fargo resumed coverage of Procept BioRobotics (PRCT) with an Overweight rating and $112 price target The firm believes aquablation remains early stages in its adoption, which will be further supported by a new product cycle, the analyst tells investors in a research note. Procept is comfortable with 2025 consensus estimates, Wells says, adding that the firm is receiving “generally positive” physician feedback on Hydros.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Procept BioRobotics initiated with an Overweight at Morgan Stanley
- Procept BioRobotics initiated with a Hold at Jefferies
- PROCEPT BioRobotics (PRCT) Continues to Invest in Labor-Saving Robotics
- Procept BioRobotics price target raised to $105 from $95 at Truist
- Procept BioRobotics 1.92M share Spot Secondary priced at $91.00